Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 7, 2013, Pages 1167-1173

  Kim, Mun Ock ^a   Lee, Su Ui ^a   Lee, Hyun Jun ^a   Choi, Kwangman ^a   Kim, Hyeongki ^a   Lee, Sangku ^a   Oh, Soo Jin ^a   Kim, Sunhong ^a,b   Kang, Jong Soon ^a   Lee, Hyun Sun ^a   Kwak, Young Shin ^c   Cho, Sungchan ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Korea University   (South Korea)

Author keywords

Diacylglycerol acyltransferase 2; Isatin; Metabolic disease; Small molecule inhibitor; Triacylglycerol

Indexed keywords

COMPOUND 122; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; ENZYME INHIBITOR; OLEOYL COENZYME A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL STRAIN HEK293; CELL STRAIN HEPG2; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; LIPOGENESIS; LIVER CELL; MAMMAL CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; VALIDATION STUDY;

ANIMALS; DIACYLGLYCEROL O-ACYLTRANSFERASE; ENZYME INHIBITORS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR STRUCTURE; SF9 CELLS; SMALL MOLECULE LIBRARIES; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84880426625     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00152     Document Type: Article

References (22)

1. Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res., 43, 134-176 (2004).
2. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H, Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Invest., 121, 2102-2110 (2011).
3. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res., 50 (Suppl.), S74-S79 (2009).
4. Tziomalos K, Athyros VG, Karagiannis A, Kolovou GD, Mikhailidis DP. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr. Drug Targets, 10, 320-327 (2009).
5. Turchetto-Zolet AC, Maraschin FS, de Morais GL, Cagliari A, Andrade CM, Margis-Pinheiro M, Margis R. Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis. BMC Evol. Biol., 11 (2011) doi: 10.1186/1471-2148-11-263.
6. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J. Lipid Res., 49, 2283-2301 (2008).
7. Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, Farese RV Jr. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J. Biol. Chem., 279, 11767-11776 (2004).
8. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV Jr. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet., 25, 87-90 (2000).
9. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem., 282, 22678-22688 (2007).
10. Levin MC, Monetti M, Watt MJ, Sajan MP, Stevens RD, Bain JR, Newgard CB, Farese RV Sr, Farese RV Jr. Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. Am. J. Physiol. Endocrinol. Metab., 293, E1772-E1781 (2007).
11. Millar JS, Stone SJ, Tietge UJ, Tow B, Billheimer JT, Wong JS, Hamilton RL, Farese RV Jr, Rader DJ. Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J. Lipid Res., 47, 2297-2305 (2006).
12. Harris CA, Haas JT, Streeper RS, Stone SJ, Kumari M, Yang K, Han X, Brownell N, Gross RW, Zechner R, Farese RV Jr. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes. J. Lipid Res., 52, 657-667 (2011).
13. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, Jiang DC, Zhang D, Lee HY, Samuel VT, Shulman GI. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl. Acad. Sci. U.S.A., 108, 5748-5752 (2011).
14. Qi J, Lang W, Geisler JG, Wang P, Petrounia I, Mai S, Smith C, Askari H, Struble GT, Williams R, Bhanot S, Monia BP, Bayoumy S, Grant E, Caldwell GW, Todd MJ, Liang Y, Gaul MD, Demarest KT, Connelly MA. The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2. J. Lipid Res., 53, 1106-1116 (2012).
15. David RB, Adrian WC, Fariborz F, Matthew MH, Shiming L, Lee AM, Yimin Q, Weiya Y. U.S. Patent 0123504 (2007).
16. Wurie HR, Buckett L, Zammit VA. Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells. FEBS J., 279, 3033-3047 (2012).
17. Medvedev A, Buneeva O, Glover V. Biological targets for isatin and its analogues: Implications for therapy. Biologics: Targets and Therapy, 1, 151-162 (2007).
18. Guenther RH, Szewczyk Jr. U.S. Patent 113606 (2011).
19. Harris C, Herker E, Farese RV Jr, Ott M. Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for coreinduced steatosis. J. Biol. Chem., 286, 42615-42625 (2011).
20. Herker E, Harris C, Hernandez C, Carpentier A, Kaehlcke K, Rosenberg AR, Farese RV Jr, Ott M. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat. Med., 16, 1295-1298 (2010).
21. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology, 45, 1366-1374 (2007).
22. Liu Y, Millar JS, Cromley DA, Graham M, Crooke R, Billheimer JT, Rader DJ. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim. Biophys. Acta, 1781, 97-104 (2008).